Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other Accumulated Expenses (2016 - 2025)

Theravance Biopharma has reported Other Accumulated Expenses over the past 13 years, most recently at $1.5 million for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 32.93% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, down 32.93% year-over-year, with the annual reading at $1.5 million for FY2025, 32.93% down from the prior year.
  • Other Accumulated Expenses was $1.5 million for Q4 2025 at Theravance Biopharma, up from $1.3 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $2.3 million in Q2 2022 and troughed at $142000.0 in Q3 2022.
  • The 5-year median for Other Accumulated Expenses is $1.5 million (2023), against an average of $1.4 million.
  • Year-over-year, Other Accumulated Expenses tumbled 92.24% in 2022 and then soared 963.38% in 2023.
  • A 5-year view of Other Accumulated Expenses shows it stood at $1.3 million in 2021, then dropped by 12.42% to $1.1 million in 2022, then increased by 8.67% to $1.2 million in 2023, then surged by 78.4% to $2.2 million in 2024, then tumbled by 32.93% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Other Accumulated Expenses are $1.5 million (Q4 2025), $1.3 million (Q3 2025), and $1.9 million (Q2 2025).